Search Results
Your search for ,had matches 18609 pages
Showing 18251 - 18300BRCA1 and BRCA2 Mutation Carriers Not at Greater Risk of Earlier Natural Menopause
Some data suggest that BRCA1 mutations are associated with occult primary ovarian insufficiency and that BRCA1 and BRCA2 mutation carriers have earlier natural menopause than noncarrier relatives. A study reported in Journal of Clinical Oncology by Ian M. Collins, MD, of Peter MacCallum Cancer...
Increased Physical Activity and Walking Reduces Breast Cancer Risk
A large epidemiology study of postmenopausal women by researchers at the American Cancer Society (ACS) has found that women who participated in at least 1 hour of vigorous physical activity every day had a 25% lower risk of breast cancer, and those who walked for at least 7 hours per week had a 14% ...
Long-Term Survivors of Childhood Cancer Exhibit Vascular Endothelial Damage
In a study reported in Journal of Clinical Oncology, Cornelia A.J. Brouwer, of the University Medical Center Groningen in the Netherlands, and colleagues assessed vascular parameters in long-term childhood cancer survivors and sibling controls. They found that survivors who had received...
Lactation May Be Linked to Triple-Negative Breast Cancer in Mexican Women
Scientific data suggest that a woman reduces her risk of breast cancer by breastfeeding, having multiple children, and giving birth at a younger age. However, a study led by the University of California, San Diego School of Medicine, indicates that women of Mexican descent may not fit that profile. ...
Genetic Anti-Inflammatory Defect May Predispose Children to Lymphoma
New research shows that children with an inherited genetic defect in a critical anti-inflammatory pathway have a genetic predisposition to lymphoma. Results of the study, published online today in Blood, reveal an important association between the genetic defect, which causes chronic intestinal...
Breast Cancer Rates Are Rising Among African American Women
Although, historically, white women aged 40 years and older have had the highest incidence rates of breast cancer, the rising rate of breast cancer among African American women—especially among women aged 50 to 59—is narrowing the gap, according to a study by American Cancer Society...
Addition of Rituximab Does Not Improve Outcome in Aggressive B-Cell Lymphoma With Skeletal Involvement, but Radiotherapy Benefit Found
In a retrospective analysis of German High-Grade Non-Hodgkin Lymphoma Study Group trials reported in Journal of Clinical Oncology, Gerhard Held, MD, of Saarland University Medical School in Homburg, and colleagues assessed the impact of rituximab (Rituxan) and radiotherapy on outcome in patients...
Treatment With Losartan May Improve Delivery of Chemotherapy Drugs in Tumors
Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In a report published in Nature Communications, investigators from Massachusetts General Hospital (MGH) described how the angiotensin...
ECC 2013: Strong Showing for Ado-Trastuzumab Emtansine in Heavily Pretreated Advanced HER2-Positive Breast Cancer
Results of the phase III TH3RESA trial show that the antibody-conjugate ado-trastuzumab (Kadcyla, previously known as T-DM1) extends progression-free survival in women with advanced HER2-positive breast cancer that progressed on two or more previous HER2-directed therapies including trastuzumab...
ECC 2013: TP53 Status Predicts Benefit From Neoadjuvant Cetuximab in Rectal Cancer
In a retrospective analysis of the randomized phase II EXPERT-C trial presented at the European Cancer Congress 2013 (Abstract LBA7), TP53 emerged as a strong, independent predictive biomarker for the benefit of cetuximab (Erbitux) in high-risk, locally advanced rectal cancer, according to...
ECC 2013: PI3KCA-Mutant Tumors Not Likely to Respond to Neoadjuvant HER2 Blockade
In patients with early breast cancer receiving anti-HER2 therapy in the NeoALTTO trial, mutations in PIK3CA were associated with lower rates of pathologic complete response, Jose Baselga, MD, reported at the European Cancer Congress 2013 (Abstract 1859) in Amsterdam. In patients treated with the...
ECC 2013: Continuous Combined Hormone Replacement Therapy Protects Against Endometrial Cancer
According to an analysis of the Women’s Health Initiative, continuous combined use of estrogen plus progestin reduces the risk of endometrial cancer among postmenopausal women. The study was reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA13) by Rowan Chlebowski, MD,...
ECC 2013: Radiation to Chest Lymph Nodes Improves Survival in Early Breast Cancer
Extending radiation to the lymph nodes behind the sternal wall and above the collarbone extends overall survival in patients with stage I to III breast cancer and does not increase toxicity compared to conventional locoregional radiation therapy, according to 10-year results of an international...
FDA Approves Neoadjuvant Pertuzumab for Early-Stage Breast Cancer
The U.S. Food and Drug Administration (FDA) today granted accelerated approval to pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and docetaxel for patients with early-stage breast cancer in the neoadjuvant setting. Pertuzumab is the first FDA-approved drug for the neoadjuvant...
ECC 2013: Molecular Sequencing Identifies Drug Targets for Cancers of Unknown Primary Origin
Cancers of unknown primary origin pose a treatment dilemma for oncologists and a great deal of anxiety for patients and their families. A study reported at the European Cancer Congress 2013 in Amsterdam (Abstract LBA39) shows that molecular profiling can identify targetable mutations in up to 80%...
ECC 2013: Multiple Studies Validate Long-Term Survival Benefit of Ipilimumab in Melanoma
There is no longer any doubt that for the treatment of metastatic or locally advanced melanoma, ipilimumab (Yervoy) conveys long-term survival benefits, according to studies presented at the European Cancer Congress 2013. In the largest survival analysis of the CTLA-4 monoclonal antibody to date...
Telomere Length May Be a Prognostic Marker for Prostate Cancer
Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by scientists at Johns Hopkins. "Doctors are looking for new ways to accurately predict...
Addition of Vorinostat to Bortezomib Results in Small Progression-Free Survival Advantage in Previously-Treated Multiple Myeloma
In a phase III study (VANTAGE 088 trial) reported in The Lancet Oncology, Meletios Dimopolous, MD, of the University of Athens, and colleagues assessed the addition of the oral HDAC inhibitor vorinostat (Zolinza) to bortezomib (Velcade) in patients with relapsed/refractory multiple myeloma. The...
Repurposed Antidepressants May Have Potential to Treat Small Cell Lung Cancer
A bioinformatics approach to repurposing drugs resulted in identification of a class of antidepressants as a potential new treatment for small cell lung cancer, according to a study published in Cancer Discovery. Based on data generated using bioinformatics, two drugs approved by the U.S. Food and ...
ASTRO: Protecting Hippocampus During Whole-Brain Radiation Substantially Reduces Rate of Memory Loss in Cancer Patients
Protecting the stem cells that reside in and around the hippocampus substantially reduces the rate of cancer patients' memory loss during whole-brain radiotherapy without a significant risk of recurrence in that area of the brain, a new study shows. Results of the phase II clinical trial of...
Increases in Melanoma Incidence and Mortality Unremitting Over 6 Decades, Study Finds
In a study reported in Journal of Clinical Oncology, Alan C. Geller, MPH, RN, of the Harvard School of Public Health, and colleagues assessed long-term trends in the incidence and mortality of melanoma in Connecticut, a state with complete and consistent tumor registration. They found...
For Pregnant Women With Lymphoma, Standard Combination Chemotherapy Given After First Trimester Associated With Few Complications
Lymphoma is the fourth most frequent cancer to occur during pregnancy. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, of Tufts University Medical School, and colleagues examined treatment, complications, and outcomes for Hodgkin lymphoma...
Large Retrospective Study Finds Association Between Marriage and Cancer Outcomes
New results from a large retrospective study of the National Cancer Institute’s SEER database, published in the Journal of Clinical Oncology, show that patients with cancer who were married at the time of diagnosis live markedly longer compared to unmarried patients. Researchers also found...
Abiraterone Acetate/Prednisone Combination Delays Decline in Quality of Life in Men With Metastatic Prostate Cancer
According to a study published in The Lancet Oncology, abiraterone acetate (Zytiga) taken in conjunction with prednisone significantly delays progression of pain and quality of life deterioration in men with metastatic castration-resistant prostate cancer. The study was led by Ethan Basch, MD,...
Phase II Study Shows Activity of Selective Aurora A Kinase Inhibitor Alisertib in Relapsed/Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphoma
Aurora A kinase is overexpressed in aggressive lymphomas and may correlate with more histologically aggressive forms of disease. In a phase II study reported in Journal of Clinical Oncology, Jonathan W. Friedberg, MD, of University of Rochester Wilmot Cancer Center, and colleagues assessed the...
Colonoscopy Associated With Reduction in Overall, Distal, and Proximal Colorectal Cancer Incidence and Mortality
Colonoscopy and sigmoidoscopy have been shown to provide protection against colorectal cancer, but the magnitude and duration of protection, particularly against proximal colon cancer, remain undefined. A study of long-term colorectal cancer incidence and mortality after lower endoscopy reported in ...
ASTRO: Younger Adults With a Limited Number of Brain Metastases Have Improved Overall Survival After Stereotactic Radiosurgery Alone
When treated with stereotactic radiosurgery that is not combined with whole-brain radiotherapy, adult brain cancer patients who were 50 years old and younger were found to have improved survival, according to research presented on Sunday, September 22, at the American Society for Radiation...
ASTRO: Proton Therapy Yields Encouraging Outcomes for Pediatric Brain Tumor Patients
When used to treat pediatric patients with intracranial malignant tumors, proton therapy may limit the toxicity of radiation therapy while preserving tumor control, according to research presented on Sunday, September 22, at the American Society for Radiation Oncology’s 55th Annual Meeting...
ASTRO: Cisplatin Plus Radiation Therapy for Advanced Cervical Cancer Improves Disease-Free Survival vs Radiotherapy Alone
Adding the chemotherapy drug cisplatin to a treatment plan of radiation therapy and high–dose rate brachytherapy for stage IIIB cervical cancer is beneficial, according to research presented on September 22, 2013, at the American Society for Radiation Oncology’s 55th Annual Meeting...
ASTRO: Fewer Weeks of Neoadjuvant Hormone Therapy Reduces Side Effects in Patients With Intermediate-Risk Prostate Cancer
A shorter course of androgen suppression therapy prior to radiation therapy, when compared to an extended course of androgen suppression therapy, yields comparable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the...
ASTRO: Long-Term Androgen Deprivation in Patients With Intermediate-Risk Prostate Cancer Does Not Improve Overall Survival
A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy. Investigators concluded that there were no additional benefits when compared to short-term...
Childhood Cancer Survivors Who Received Nephrotoxic Therapy May Be at Greater Risk for Late Renal Problems
A large study assessing glomerular function in adult survivors of childhood cancers who were treated with certain chemotherapy drugs or kidney surgery found that they had worse kidney function, which did not recover over time, compared with adult survivors who were not given nephrotoxic therapy....
Antiviral Treatment Improves Recurrence-Free and Overall Survival in HBV-Related Hepatocellular Carcinoma
Patients with hepatitis B virus (HBV)-related hepatocellular carcinoma have poor postoperative prognosis. In a study reported in Journal of Clinical Oncology, Jianhua Yin, MD, of the Second Military Medical University in Shanghai, and colleagues assessed the effects of nucleotide/nucleoside analog...
NCCN: PET-Guided Therapy for Hodgkin Lymphoma Moving Into Clinical Practice
Interim positron emission tomography (PET) scan is being used to guide risk-adapted therapy in patients with early-stage and advanced-stage Hodgkin lymphoma for clinical research at academic centers, and experts predict that this will become standard of care in clinical practice. At the NCCN 8th...
Deficient DNA Mismatch Repair Associated With Favorable Prognosis in Proximal Tumors in Stage III Colon Cancer Patients Receiving Adjuvant FOLFOX
In an analysis reported in Journal of Clinical Oncology, Frank A. Sinicrope, MD, of the Mayo Clinic and North Central Cancer Treatment Group (NCCTG), and colleagues investigated the association of deficient DNA mismatch repair with prognosis in patients with stage III colon cancer treated with...
Reduced Long-Term Survival and Increased Risk of Secondary Cancer in Younger Women After External Pelvic Radiation for Early-Stage Endometrial Cancer
In a study reported in Journal of Clinical Oncology, Mathias Onrud, MD, of Norwegian Radium Hospital, Oslo University Hospital, and colleagues assessed outcomes in the follow-up of the Norwegian Radium Hospital trial to determine long-term effects of external beam radiation therapy in the adjuvant...
Japanese Study Shows Endoscopic Dual Tracer Method for Sentinel Node Mapping in Gastric Cancer Is Safe and Accurate
In a study reported in Journal of Clinical Oncology, Yuko Kitagawa, MD, FACS, of Keio University School of Medicine, and colleagues found that sentinel node mapping using a standardized dual tracer endoscopic injection technique was safe and accurate in patients with gastric cancer. Study Details ...
Widespread Contraindicated Use of Bevacizumab in Elderly Patients
In a study reported in Journal of Clinical Oncology, Dawn L. Hershman, MD, MS, of Columbia University, and colleagues assessed the use of bevacizumab in older patients with metastatic breast, lung, or colon cancer. They found that bevacizumab (Avastin) was contraindicated in approximately one-third ...
Presence of RAS Mutations in Metastatic Colorectal Cancer Predictive of Negative Response to Panitumumab/FOLFOX4 Treatment
Patients with metastatic colorectal cancer that harbors KRAS mutations in exon 2 do not benefit from anti-EGFR therapy. However, other activating RAS mutations may predict poorer outcome with anti-EGFR therapy. In an analysis reported in The New England Journal of Medicine by Jean-Yves Douillard,...
Young Breast Cancer Patients May Overestimate Benefit of Contralateral Prophylactic Mastectomy
Young women with breast cancer may overestimate the risk that cancer will occur in their other healthy breast and decide to undergo contralateral prophylactic mastectomy, a survey conducted by Dana-Farber Cancer Institute investigators indicated. The survey also shows that many patients may opt for ...
PDK1 Gene Identified as New Target for Melanoma Treatment
According to new research at Sanford-Burnham Medical Research Institute a gene encoding the enzyme phosphoinositide-dependent kinase-1 (PDK1) plays an essential role in the development and progression of melanoma. The finding, published online in Oncogene, may offer insight toward a new approach to ...
Addition of Bevacizumab to Capecitabine Improves Progression-Free Survival in Elderly Patients with Previously Untreated Metastatic Colorectal Cancer
Elderly patients are often underrepresented in clinical trials of metastatic colorectal cancer. In a phase III study (AVEX trial) reported in The Lancet Oncology, David Cunningham, MD, of Royal Marsden Hospital in London and colleagues assessed the addition of bevacizumab (Avastin) to capecitabine...
Tremelimumab Shows Some Activity in Chemotherapy-Resistant Advanced Malignant Mesothelioma, Phase II Study Finds
Tremelimumab is an anticytotoxic T-lymphocyte antigen 4 (CTLA4) monoclonal antibody, a class of inhibitor that has shown activity in multiple tumor types. Ipilimumab (Yervoy), another agent in this class, was found to significantly prolong overall survival in metastatic melanoma despite a...
Exploratory Analysis Suggests Response-Guided Neoadjuvant Therapy for Breast Cancer May Improve Survival
In an exploratory analysis of long-term survival data from the GeparTrio trial reported in Journal of Clinical Oncology, Gunter von Minckwitz, MD, of the German Breast Group in Neu-Isenburg, and colleagues found that response-guided neoadjuvant chemotherapy appears to improve disease-free survival...
Phase II Study Shows Durable Effect of Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma
In a phase II study (MCL-001, EMERGE) reported in Journal of Clinical Oncology, Andre Goy, MD, of Hackensack University Medical Center, and colleagues evaluated the use of single-agent lenalidomide (Revlimid) in bortezomib (Velcade)-treated patients who had relapsed/refractory mantle cell lymphoma. ...
New Plasma Biomarker Identified for the Diagnosis of Lung Cancer
A new plasma biomarker, isocitrate dehydrogenase 1 (IDH1), has been shown to be more sensitive in detecting non–small cell lung cancer (NSCLC) than currently used biomarkers, including CEA, Cyfra21-1, and CA125, according to a study published in Clinical Cancer Research. The study by Jie He,...
Test Could Identify Which Prostate Cancers Require Treatment
The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center (CUMC). Use of this three-gene...
Tivozanib Improves Progression-Free Survival but Not Overall Survival vs Sorafenib in Metastatic Renal Cell Carcinoma
Tivozanib is a selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor 1 (VEGFR1), -2, and -3. In a phase III trial reported in Journal of Clinical Oncology by Robert J. Motzer, MD, of Memorial Sloan-Kettering Cancer Center (MSKCC) and colleagues, tivozanib was found to...
Models Estimate Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
In a study reported in The New England Journal of Medicine, Annette McWilliams, MD, of Vancouver General Hospital, and colleagues analyzed data from subjects undergoing low-dose computed tomography (CT) screening for lung cancer to identify factors that might predict whether lung nodules found on...
Ipilimumab Fails to Significantly Prolong Survival in Patients With Advanced Prostate Cancer
Bristol-Myers Squibb Company, the manufacturer of ipilimumab (Yervoy), released results from its phase III randomized double-blind study investigating the drug in men with metastatic castration-resistant prostate cancer. The study findings show that ipilimumab, a monoclonal antibody that blocks the ...
